journal article·2021-08

Epigallocatechin gallate/L-ascorbic acid–loaded poly-γ-glutamate microneedles with antioxidant, anti-inflammatory, and immunomodulatory effects for the treatment of atopic dermatitis

Yu-Hsiu Chiu, Yan-Wei Wu, Jui-I Hung, Mei-Chin Chen

Acta Biomaterialia· Volume 130
Publisher page

Abstract

Epigallocatechin gallate (EGCG) is a potential therapeutic agent for treatment of atopic dermatitis (AD) due to its antioxidant and anti-inflammatory activities. However, inherent instability of EGCG greatly limits its bioavailability and clinical efficacy. In this study, we developed a poly-γ-glutamate (γ-PGA)-based microneedle (MN) formulation capable of maintaining EGCG's stability and efficiently delivering EGCG into the skin to ameliorate AD symptoms. The γ-PGA MN can not only protect EGCG from oxidation, but also serve as an immunomodulator to downregulate T helper type 2 (Th2)-type immune responses. Encapsulation of EGCG into the γ-PGA MN and utilization of L-ascorbic acid (AA) as a stabilizer preserved 95% of its structural stability and retained 93% of its initial antioxidant activity after 4 weeks of storage. Once-weekly administration of EGCG/AA-loaded MNs to an Nc/Nga mouse model of AD for 4 weeks significantly ameliorated skin lesions and epidermal hyperplasia by reducing serum IgE (from 12156 ± 1344 to 5555 ± 1362 ng/mL) and histamine levels (from 81 ± 18 to 40 ± 5 pg/mL) and inhibiting IFN-γ (from 0.10 ± 0.01 to 0.01 pg/mg total protein) and Th2-type cytokine production, when compared to the AD (no treatment) group (p < 0.05). Notably, once-weekly MN therapy was at least as effective as the daily topical application of an EGCG + AA solution but markedly reduced the administration frequency and required dose. These results show that EGCG/AA-loaded γ-PGA MNs may be a convenient and promising therapeutic option for AD treatment. STATEMENT OF SIGNIFICANCE: This study describes epigallocatechin gallate (EGCG)/L-ascorbic acid (AA)-loaded poly-γ-glutamate (γ-PGA) microneedles (MN) capable of providing antioxidant, anti-inflammatory, and immunomodulatory effects on inflamed skin for ameliorating atopic dermatitis (AD) symptoms in Nc/Nga mice. After skin insertion, the γ-PGA MN can be quickly dissolved in the skin and remain in the dermis for sustained release of encapsulated active ingredients for 6 days. We demonstrated that once-weekly MN therapy effectively alleviated skin lesions and modulated immune response to relieve Th2-polarized allergic response in mice. Once-weekly MN dosing regimen may provide patients with a more convenient, therapeutically equivalent option to daily topical dosing, and may increase compliance and long-term persistence with AD therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Dermatology and Skin Diseases · Allergic Rhinitis and Sensitization · Contact Dermatitis and Allergies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (72)

Show source-provided references
1. Natural history and risk factors of atopic dermatitis in children10.4168/aair.2015.7.2.101 ↗
3. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema10.1111/j.1742-1241.2006.01047.x ↗
4. Effects of childhood atopic eczema on the quality of life
5. Poly-γ-glutamate microneedles as transdermal immunomodulators for ameliorating atopic dermatitis-like skin lesions in Nc/Nga mice10.1016/j.actbio.2020.07.029 ↗
6. Advances in atopic dermatitis in 201510.1016/j.jaci.2016.10.004 ↗
7. Multifactorial skin barrier deficiency and atopic dermatitis: essential topics to prevent the atopic march10.1016/j.jaci.2016.06.002 ↗
8. The skin barrier, atopic dermatitis and allergy: a role for Langerhans cells?10.1016/j.it.2007.05.003 ↗
9. Oral administration of poly-γ-glutamate ameliorates atopic dermatitis in Nc/Nga mice by suppressing Th2-biased immune response and production of IL-17A10.1038/jid.2013.389 ↗
10. IL-17 and IL-22 in atopic allergic disease10.1016/j.coi.2010.10.013 ↗
11. The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults10.1155/2016/3164734 ↗
12. Oxidative stress responses-what have genome-scale studies taught us?10.1186/gb-2002-3-7-reviews1019 ↗
13. DJ-1 regulates mast cell activation and IgE-mediated allergic responses10.1016/j.jaci.2012.10.012 ↗
14. Oxidative stress in atopic dermatitis10.1155/2016/2721469 ↗
15. Oxidative stress and inflammation: what polyphenols can do for us?10.1155/2016/7432797 ↗
16. The role of reactive oxygen species in regulating T cell-mediated immunity and disease10.4110/in.2018.18.e14 ↗
17. Oxidative microenvironment exerts an opposite regulatory effect on cytokine production by Th1 and Th2 cells10.1016/j.molimm.2007.05.008 ↗
18. New therapies for atopic dermatitis: additional treatment classes10.1016/j.jaad.2017.12.024 ↗
19. The challenge of managing atopic dermatitis in the United States
20. Biological therapies for atopic dermatitis: a systematic review
21. Microneedle-assisted genome editing: a transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders10.1126/sciadv.abe2888 ↗
22. High-dose steroid dissolving microneedle for relieving atopic dermatitis
23. Stability of (−)-epigallocatechin gallate and its activity in liquid formulations and delivery systems10.1016/j.jnutbio.2016.01.002 ↗
24. What are the differences between ascorbic acid and NADH as hydride and electron sources in vivo on thermodynamics, kinetics, and mechanism?10.1021/jp2067974 ↗
25. Free radicals, natural antioxidants, and their reaction mechanisms10.1039/C4RA13315C ↗
26. Inhibition of xanthine oxidase and suppression of intracellular reactive oxygen species in HL-60 cells by theaflavin-3,3′-digallate,(−)-epigallocatechin-3-gallate, and propyl gallate10.1021/jf000066d ↗
27. Epigallocatechin-3-gallate (EGCG) reduces liver inflammation, oxidative stress and fibrosis in carbon tetrachloride (CCl4)-induced liver injury in mice10.1016/j.tox.2010.04.014 ↗
28. Green tea epigallocatechin-3-gallate inhibits microsomal prostaglandin E2 synthase-110.1016/j.bbrc.2009.08.005 ↗
29. Effects of purified green and black tea polyphenols on cyclooxygenase-and lipoxygenase-dependent metabolism of arachidonic acid in human colon mucosa and colon tumor tissues10.1016/S0006-2952(01)00767-5 ↗
30. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions10.1080/10408690390826464 ↗
31. Encapsulation of natural polyphenolic compounds; a review10.3390/pharmaceutics3040793 ↗
32. Multifunctional activities of green tea catechins in neuroprotection10.1159/000085385 ↗
33. Bioactive dietary polyphenolic compounds reduce nonheme iron transport across human intestinal cell monolayers10.1093/jn/138.9.1647 ↗
34. Neuroprotective molecular mechanisms of (−)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties10.1007/s12263-009-0143-4 ↗
35. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents10.1016/j.pneurobio.2007.06.001 ↗
36. Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling, Free Radic
37. Epigallocatechin-3-gallate improves Dermatophagoides pteronissinus extract-induced atopic dermatitis-like skin lesions in Nc/Nga mice by suppressing macrophage migration inhibitory factor10.1016/j.intimp.2008.04.002 ↗
38. Epigallocatechin-3-gallate inhibits inflammation and epithelialmesenchymal transition through the PI3K/AKT pathway via upregulation of PTEN in asthma
39. Epigallocatechin-3-gallate inhibits mast cell degranulation, leukotriene C4 secretion, and calcium influx via mitochondrial calcium dysfunction, Free Radic
40. Inhibitory effects of epigallocatechin gallate on compound 48/80-inducedmast cell activation and passive cutaneous anaphylaxis10.1038/emm.2005.39 ↗
41. Absorption of (–)-epigallocatechin gallate into the circulation system of rats10.1271/bbb.59.1558 ↗
42. Chemiluminescence–high-performance liquid chromatographic determination of tea catechin,(−)-epigallocatechin 3-gallate, at picomole levels in rat and human plasma10.1006/abio.1997.2098 ↗
43. Enhancement of the permeability and activities of epigallocatechin gallate by quaternary ammonium chitosan/fucoidan nanoparticles10.1016/j.carbpol.2020.116312 ↗
44. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model10.1016/j.jconrel.2019.03.010 ↗
45. Natural and edible biopolymer poly-γ-glutamic acid: synthesis, production, and applications10.1002/tcr.20061 ↗
46. Validation of a high performance liquid chromatography method for the stabilization of epigallocatechin gallate10.1016/j.ijpharm.2014.08.053 ↗
47. Comparative study of antioxidant properties and total phenolic content of 30 plant extracts of industrial interest using DPPH, ABTS, FRAP, SOD, and ORAC assays10.1021/jf803011r ↗
48. The Easi Evaluator Group, The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis10.1034/j.1600-0625.2001.100102.x ↗
49. Tea catechin auto-oxidation dimers are accumulated and retained by Caco-2 human intestinal cells10.1016/j.nutres.2010.05.006 ↗
50. Effective use of reducing agents and nanoparticle encapsulation in stabilizing catechins in alkaline solution10.1016/j.foodchem.2010.03.027 ↗
51. Role of vitamin C in skin diseases10.3389/fphys.2018.00819 ↗
52. The roles of vitamin C in skin health10.3390/nu9080866 ↗
53. Digallate dimers of (−)-epigallocatechin gallate inactivate herpes simplex virus10.1128/AAC.05531-11 ↗
54. Structure−activity relationships of tea compounds against human cancer cells10.1021/jf062276h ↗
55. A single ascending dose study of epigallocatechin gallate in healthy volunteers10.1177/147323000303100205 ↗
56. Protective effects of theasinensin A against carbon tetrachloride-induced liver injury in mice10.1039/C7FO00700K ↗
57. Chemistry and health beneficial effects of oolong tea and theasinensins10.1016/j.fshw.2015.10.002 ↗
58. Theflavins and theasinensin A derived from fermented tea have antihyperglycemic and hypotriacylglycerolemic effects in KK-Ay mice and sprague–dawley rats10.1021/jf400123y ↗
59. Animal models of atopic dermatitis10.1038/jid.2008.106 ↗
60. 7,8,4′-Trihydroxyisoflavone attenuates DNCB-induced atopic dermatitis-like symptoms in Nc/Nga mice10.1371/journal.pone.0104938 ↗
61. Pellino1 promotes chronic inflammatory skin disease via keratinocyte hyperproliferation and induction of the T helper 17 response10.1038/s12276-020-00489-4 ↗
62. Caffeoyl–Pro–His amide relieve DNCB-induced atopic dermatitis-like phenotypes in BALB/c mice10.1038/s41598-020-65502-2 ↗
63. Topical anti-inflammatory and anti-oxidative effects of porcine placenta extracts on 2,4-dinitrochlorobenzene-induced contact dermatitis10.1186/s12906-018-2396-1 ↗
64. Cytoprotective effect of epigallocatechin gallate (EGCG)-5′-O-α-glucopyranoside, a novel EGCG derivative10.3390/ijms19051466 ↗
65. Anti-inflammatory effect of epigallocatechin gallate in a mouse model of ovalbumin-induced allergic rhinitis10.1016/j.intimp.2017.05.030 ↗
66. Stability of ascorbic acid in aqueous and aqueous-organic solutions for quantitative determination10.1134/S1061934807080096 ↗
67. Latent TGFβ1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder10.1038/sj.emboj.7600183 ↗
68. Therapeutic effects of bee venom and its major component, melittin, on atopic dermatitis in vivo and in vitro10.1111/bph.14487 ↗
69. CD8+ T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-γ, IL-13, IL-17, and IL-2210.1038/jid.2012.456 ↗
70. Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model10.1111/j.1365-2249.2004.02649.x ↗
71. Ameliorative effect of orally administered different linoleic acid/α-linolenic acid ratios in a mouse model of DNFB-induced atopic dermatitis10.1016/j.jff.2019.103754 ↗
72. IFN-γ reduces epidermal barrier function by affecting fatty acid composition of ceramide in a mouse atopic dermatitis model10.1155/2019/3030268 ↗